AU Patent

AU2013201219A1 — Azetidine and cyclobutane derivatives as jak inhibitors

Assigned to Incyte Holdings Corp · Expires 2013-03-21 · 13y expired

What this patent protects

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK 5 inhibitors useful in the treatment of JAK-associated disea…

USPTO Abstract

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK 5 inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013201219A1
Jurisdiction
AU
Classification
—
Expires
2013-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.